Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

NCT06235918 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinomas
Resectable Head and Neck Squamous-cell Carcinoma

Interventions

DRUG: Tislelizumab
DRUG: Nab-paclitaxel
DRUG: Carboplatin

Sponsor

Xiang Lu